Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Aptose Biosciences Price Performance

Aptose Biosciences stock opened at $0.40 on Friday. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.32. The firm has a market capitalization of $7.17 million, a PE ratio of -0.06 and a beta of 1.26. The company’s 50-day moving average is $0.40 and its 200-day moving average is $0.74.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences as of its most recent filing with the SEC. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.